{
    "organizations": [],
    "uuid": "3be37b8dc6a024ce52624ca0922509cb6bbd86e1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-approves-prolia-for-glucocorti/brief-fda-approves-prolia-for-glucocorticoid-induced-osteoporosis-idUSASC0A33K",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Amgen Inc:\n* FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS\n* FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS\n* AMGEN INC - SAFETY RESULTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF PROLIA\n* AMGEN INC - APPROVAL OF PROLIA FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS IS BASED ON DATA FROM A PHASE 3 STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T04:03:00.000+03:00",
    "crawled": "2018-05-22T19:18:34.056+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "amgen",
        "inc",
        "fda",
        "approves",
        "denosumab",
        "osteoporosis",
        "fda",
        "approves",
        "denosumab",
        "osteoporosis",
        "amgen",
        "inc",
        "safety",
        "result",
        "consistent",
        "known",
        "safety",
        "profile",
        "prolia",
        "amgen",
        "inc",
        "approval",
        "prolia",
        "osteoporosis",
        "based",
        "data",
        "phase",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}